Personalised medicine for IPF: getting closer, but not there yet

The Lancet Respiratory Medicine

Volumn 5, Issue 11, 2017, Pages 836-837

  Sato, Seidai ^a,b   Kolb, Martin R J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT;

FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENE; HUMAN; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

HUMANS; PRECISION MEDICINE;

EID: 85029574905     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30348-X     Document Type: Note

References (12)

1. Raghu, G, Collard, HR, Egan, JJ, et al., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. Hopkins, RB, Burke, N, Fell, C, Dion, G, Kolb, M, Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 48 (2016), 187–195.
3. Fernandez Perez, ER, Daniels, CE, Schroeder, DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137 (2010), 129–137.
4. Hambly, N, Kolb, M, Pathways to precision medicine in idiopathic pulmonary fibrosis. Time to relax?. Am J Respir Crit Care Med 194 (2016), 1315–1317.
5. Herazo-Maya, JD, Noth, I, Duncan, SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med, 5, 2013, 205ra136.
6. Herazo-Maya, JD, Sun, J, Molyneaux, PL, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort. Lancet Respir Med, 2017 published online Sept 20. http://dx.doi.org/10.1016/S2213-2600(17)30349-1.
7. Richards, TJ, Kaminski, N, Baribaud, F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185 (2012), 67–76.
8. Ley, B, Ryerson, CJ, Vittinghoff, E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156 (2012), 684–691.
9. Natsuizaka, M, Chiba, H, Kuronuma, K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190 (2014), 773–779.
10. Taguchi, Y, Ebina, M, Hashimoto, S, et al., Pirfenidone Clinical Study Group in Japan. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: extended analysis of phase III trial in Japan. Respir Investig 53 (2015), 279–287.
11. Kolb, M, Richeldi, L, Behr, J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 72 (2017), 340–346.
12. Okuda, R, Hagiwara, E, Baba, T, Kitamura, H, Kato, T, Ogura, T, Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 107 (2013), 1431–1437.